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ABSTRACT
Evolution of the breast cancer genome from pre-invasive stages to asynchronous 
metastasis is complex and mostly unexplored, but highly demanded as it may provide 
novel markers for and mechanistic insights in cancer progression. The increasing use 
of personalized therapy of breast cancer necessitates knowledge of the degree of 
genomic concordance between different steps of malignant progression as primary 
tumors often are used as surrogates of systemic disease. Based on exome sequencing 
we performed copy number profiling and point mutation detection on successive steps 
of breast cancer progression from one breast cancer patient, including two different 
regions of Ductal Carcinoma In Situ (DCIS), primary tumor and an asynchronous 
metastasis. We identify a remarkable landscape of somatic mutations, retained 
throughout breast cancer progression and with new mutational events emerging 
at each step. Our data, contrary to the proposed model of early dissemination of 
metastatic cells and parallel progression of primary tumors and metastases, provide 
evidence of linear progression of breast cancer with relatively late dissemination 
from the primary tumor. The genomic discordance between the different stages of 
tumor evolution in this patient emphasizes the importance of molecular profiling of 
metastatic tissue directing molecularly targeted therapy at recurrence.
INTRODUCTION
Breast cancer progression results from stochastic 
events leading to the acquisition of genomic alterations 
resulting in reduced apoptosis, replicative immortality, 
evasion of growth suppressors, uncontrolled proliferation, 
reprogrammed energy metabolism, evasion of immune 
destruction, angiogenesis, invasion and metastasis [1]. 
Approximately 500 genes are known to be involved in 
carcinogenesis [2], but relatively little is known about the 
genes driving metastatic progression. Metastases represent 
the final products of a multi-step biological process as the 
metastatic cascade involves many critical steps, which are 
still poorly understood. Different genes are believed to be 
involved at different stages, as the metastatic process poses 
very diverse challenges to the cell, including detachment, 
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motility, invasion, survival in circulation, extravasation, 
adaptation to a new environment and organ-specific 
colonization [3]. Cancer progression may be regarded as 
a process of natural selection, where genomic alterations 
conferring a selective advantage for the cell in a given 
environment and time point of the progression process as 
well as selection pressures provided by treatment results in 
the formation of the most aggressive clones.
Monoclonal origin of cancer, as proposed by Nowell 
in 1976 [4] is widely accepted. However, controversy 
exists between two fundamental models of malignant 
progression, addressing the issue of the timing of 
metastasis-enabling genomic alterations and the degree 
of genomic concordance between primary tumors and its 
metastases. According to the linear progression model, 
the malignant cells pass through multiple successive 
rounds of genetic changes and selection within the 
primary tumor microenvironment, before tumor cell 
dissemination successfully results in a metastatic lesion. 
From this perspective, metastases are seeded by the most 
advanced and aggressive clone that should also dominate 
the primary tumor [5]. The parallel progression model 
proposes parallel, independent progression of metastases 
arising from early disseminated tumor cells and predicts 
greater disparity between the primary tumor and metastatic 
lesions. The model emphasizes independent accumulation 
of genetic and epigenetic alterations as the metastasis is 
subject to site-specific selection pressures [6].
Somatic copy number alterations and point 
mutations contribute to malignant progression, by 
altering the expression or functions of cancer driver 
genes. DNA breakpoints are non-randomly distributed 
and breakpoint hotspots are influenced by chromatin 
architecture [7], replication timing [8], specific repeat 
sequences, G-quadruplex sequences and hypomethylation 
[9]. Distinct patterns have been found for common 
cancer breakpoint hotspots and cancer-type-specific 
breakpoint hotspots [10]. Somatic copy number events can 
accumulate progressively or result from punctuated bursts 
of evolution in catastrophic events like chromothripsis 
[11]. Oncogene amplification can take place either in 
double minute chromosomes or intrachromosomally 
through breakage-fusion-bridge cycles [12].
We set out to illuminate some of the unresolved 
issues of breast cancer progression. It is unknown when 
actually the metastasis founder cell leaves the primary 
tumor and how similar early and late stages of breast 
cancer progression are at the genetic level. Another 
unresolved aspect is the degree of clonal diversity within 
cancer tissue. Furthermore, it has been discussed whether 
genetic aberrations accumulate gradually over time or 
result from catastrophic events. A very limited number of 
studies have included breast cancer samples separated by 
both space and time, which is needed in order to address 
such questions.
Using exome sequencing and validation using 
targeted deep sequencing we conducted genome-wide 
copy number profiling and point mutation detection on 
successive steps of breast cancer progression from one 
patient, who had received neo-adjuvant and subsequently 
adjuvant treatment, including two regions of pre-invasive 
tissue, primary tumor and an asynchronous metastasis. 
We report limited clonal heterogeneity, possibly involving 
catastrophic events and substantial genomic discordance 
between early tumor stages and the asynchronous 
metastasis with data in favor of a linear progression model.
RESULTS
Somatic events are retained throughout breast 
cancer progression
To investigate the genome evolution through breast 
cancer progression, successive tumor samples from an 
estrogen receptor positive, HER2-negative breast cancer 
patient undergoing mastectomy and an asynchronous 
metastasis were collected and thoroughly analyzed using 
next generation sequencing. The patient had initially been 
treated with five series of neo-adjuvant Cyclophosphamide, 
Epirubicin and Fluorouracil (CEF). From the mastectomy 
specimen two topologically separated regions of Ductal 
Carcinoma in Situ (DCIS) and a primary tumor region were 
secured. In addition to the neo-adjuvant chemotherapy, 
all tumor samples included in the study had been subject 
to endocrine treatment with Tamoxifen or Anastrozole. 
Following mastectomy, the patient received four series of 
Taxotere/Gemcitabine and radiation therapy. In spite of the 
extensive therapy and ongoing endocrine treatment, the 
patient experienced recurrence after 4.05 years and from 
a contralateral periclavicular lymph node an asynchronous 
metastasis was biopsied and included in the study. Exome 
sequencing was performed on DNA from each tumor 
sample and somatic copy number mutations were detected 
by two supplementing analyses. The pseudo-CGH ngCGH, 
using simple coverage counting on tumor sequencing reads 
relative to normal reads, plottet in Log2 ratios, reveal copy 
number imbalances between tumor tissue and matched 
normal tissue. These genomic quantity measurements of 
tumor sequencing data relative to normal, were supported 
by a plot of B Allele Frequencies (BAFs) measuring the 
allelic imbalance in the tumor tissue. These BAFs are 
not displaying the usual variant allele frequency, as they 
include only positions with known heterozygote SNPs of 
the patient. Hence, these BAFs support copy number events 
by providing information about the fraction of sequenced 
cells in the cancer sample to be affected by a somatic copy 
number event, and enable detection of subclonality within 
the cancer cell population. For a detailed description of the 
ngCGH technique and the accompanying BAFs, see the 
methods section.
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Genome-wide displays of Log2 ratios and 
corresponding BAFs from each step of malignant 
progression are displayed in Figure 1. Our results reveal 
overall striking similarities in copy number patterns 
between different steps of cancer evolution in the studied 
patient. In Table 1 all copy number events and the 
concordance of the aberrations between the samples are 
listed. All steps of malignant progression display Loss of 
Heterozygosity (LOH) of the entire chromosome 2, which 
is also seen in the BAF plot, confirming that all of the 
malignant cells have lost one of the alleles. Similarly, 
copy number losses on 4p, 6q, 8p, 9q, 11q, 13p-q, 14q, 
16p, 16q, 17p, 17q, 19q and 21q are supported by the 
BAFs and are present in all samples. Overview of copy 
number aberrations in all the samples are provided in 
Supplementary Figures 1–4. Chromosome 8, 11 and 16 
are subjects to widespread amplifications, but whereas the 
events on chromosome 11 and 16 are a common trait of 
this cancer genome, chromosome 8q undergoes additional 
amplification during breast cancer progression. All 
samples display high copy number gain at 8q21.3–24.3, 
containing the known oncogenic driver MYC (8q24.21), 
but additional events arise in the later stages, and thus 
chromosome 8 appears repeatedly in Table 1. In total, 36 
copy number events were identified in DCIS 1, comprising 
25 loss events and 11 gain events, as seen in Table 1. 
The exact localization of breakpoints found in DCIS 1 
are retained in all later stages of tumor progression, 
confirming common ancestry of the malignant cells of 
progression.
The copy number evolution of the studied cancer 
genome is displayed in Figure 2. A total of 99.14 Mb, 
148.29 Mb, 213.08 Mb and 239.55 Mb were copy gained 
and 786.27 Mb, 876.05 Mb, 1014.93 Mb and 1902.27 Mb 
were copy lost in DCIS 1, DCIS 2, primary tumor and 
asynchronous metastasis, respectively (Supplementary 
Table 2). As all aberrations are retained in later steps, 
100% of the copy number events found in DCIS 1, 
DCIS 2 and primary tumor are found in the asynchronous 
metastasis. Of the 2141.82 Mb copy number events found 
in the asynchronous metastasis only 41.33% are present 
in DCIS 1. Of the 1228.01 Mb copy number events 
found in the primary tumor 72.10% are present in DCIS 1. 
Of the 1024.34 Mb copy number events found in DCIS 2 
86.43% are present in DCIS 1. These concordance levels 
thus argue for a linear evolution of the analyzed cancer 
genome.
Somatic variant calling on the exome sequencing 
data provided 73 nonsynonymous, stopgain, splice and 
frameshift mutations, shown in Supplementary Table 3. 
To validate the mutations, targeted deep sequencing of 
the positions was performed. Sixtyfive point mutations 
could be validated. Validated point mutations combined 
with copy number events are displayed in Figure 3. 
Nucleotide changes, amino acid changes and functional 
prediction scores are displayed in Supplementary Table 4. 
A venn diagram of the mutational concordance between 
the samples is shown in Figure 4. Of the 65 validated point 
mutations detected, no mutations were private to DCIS 1 
or the primary tumor while one mutation is exclusive to 
DCIS 2. Twenty-three mutations were shared by all steps 
of malignant progression and 17 were exclusively found 
in the metastasis.
Subclonality within DCIS and evolution of 
somatic events
The DCIS 2 sample displays three copy number loss 
events and five copy number gain events not found in the 
other pre-invasive sample. All newly acquired aberrations 
remain throughout later stages of progression, again 
confirming the common ancestry between the later stages and 
this malignant clone. Copy number losses on chromosome 
9p and 20p are subclonal events, supported by subclonal 
BAFs, illustrating that only a fraction of the malignant cells 
are affected by the loss event. For copy number gain events 
it is not possible to detect whether events are subclonal or 
complete events, as a region can be massively amplified 
within a subclone of cells or moderately gained in all 
malignant cells. The three copy number gain events on 
chromosome 19q and Xq may be subclonal events, which 
is suggested by BAFs not splitting out to the same extend as 
seen in the primary tumor and the metastasis.
Subclonality within the primary tumor and 
subclonal origin of the metastatic cell
The primary tumor displays six additional copy number 
loss events and nine copy number gain events, solely shared 
between the primary tumor and the asynchronous metastasis, 
but not present in the pre-invasive tissue, suggesting that these 
events might contribute to invasiveness. Copy number losses 
on chromosome 19p and 20p are subclonal events in the 
primary tumor but a “pure” phenomenon in the asynchronous 
metastasis. Thus, a subclonal cell of the primary tumor was 
the one to succeed in forming the metastasis. The subclonal 
origin of the metastasis founder cell is further supported 
by point mutation data. The mutation frequencies in the 
PITPNM2, KCNQ2, MYLK, LRRC52 and TMTC1 genes are 
subclonal with BAFs in the primary tumor around 10–15% 
as seen in Figure 3 and are “purified” to comprise a complete 
heterozygote mutation frequency with BAFs around 40–48% 
in the metastasis.
Excessive increase in somatic events and 
subclonality within the asynchronous metastasis
The asynchronous metastasis retains all previous 
aberrations and displays 18 copy number loss and 18 
copy number gain events exclusive to the metastasis, 
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Figure 1: Genome wide displays of copy number mutation data. Log2 ratios and corresponding B Allele Frequencies (BAFs) 
are in upper and lower panels, respectively of each tumor sample. The Log2 ratios constitute a genomic quantity measurement of the tumor 
sample relative to the normal. The BAF plots are based on known heterozygote SNP positions of the patient, thus depicting the allelic 
imbalances of the tumor sample.
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Table 1: Copy number events within four steps of malignant progression. The x informs whether the 
event is present within each tumor sample. LOH: loss of heterozygosity. HL: homozygote loss. OCL: 
one copy loss. CG: Copy gain. HCG: high copy gain. VHCG: very high copy gain. EHCG: extremely 
high copy gain. *denotes that for copy gain events it is not possible to discriminate between copy gain 
within all the malignant cells or higher amplification within a subclone of cells
Chr Start 
(Mb)
End 
(Mb)
Length 
(Mb)
Cytobands Type # 
genes
DCIS 
1
DCIS 2 
complete
DCIS 2 
subclone
Primary 
tumor 
complete
Primary 
tumor 
subclone
Metastasis 
complete
Metastasis 
subclone
2 0 243.19 243.19 p25.3–q37.3 LOH 1545 x x x x x x x
4 0 49.53 49.53 p16.3–p11 LOH 346 x x x x x x x
6 68.64 160.13 91.48 q12–q25.3 LOH 439 x x x x x x x
8 0 37.68 37.68 p23.3–p11.23 LOH 306 x x x x x x x
8 7.04 8.06 1.02 p23.1 HL 46 x x x x x x x
8 11.88 12.42 0.54 p23.1 HL 18 x x x x x x x
8 39.44 41.05 1.61 p11.22–11.21 LOH 6 x x x x x x x
9 68.18 130.82 62.64 q13–q34.11 LOH 470 x x x x x x x
11 62.41 68.28 5.86 q12.3–q13.2 LOH 240 x x x x x x x
11 71.11 75.90 4.79 q13.4–q13.5 LOH 79 x x x x x x x
11 85.72 87.59 1.87 q14.2 LOH 11 x x x x x x x
11 100.81 135.00 34.19 q22.1–q25 LOH 322 x x x x x x x
13 16.48 115.16 98.68 p11.1–q34 LOH 518 x x x x x x x
14 43.95 80.13 36.17 q21.2–q31.1 LOH 287 x x x x x x x
14 84.27 106.74 22.47 q31.2–q32.33 LOH 285 x x x x x x x
16 0.08 1.4 1.31 p13.3 LOH 65 x x x x x x x
16 3.04 4.48 1.44 p13.3 LOH 46 x x x x x x x
16 24.56 27.43 2.87 p12.1 LOH 16 x x x x x x x
16 32.60 33.37 0.77 p11.2 LOH 11 x x x x x x x
16 33.55 34.46 0.90 p11.2 LOH 3 x x x x x x x
16 45.61 90.35 44.74 q11.2–q24.3 LOH 446 x x x x x x x
17 0 22.59 22.59 p13.3–p11.1 LOH 414 x x x x x x x
17 25.29 41.45 16.16 q11.1–q21.31 LOH 400 x x x x x x x
19 57.79 59.12 1.33 q13.43 LOH 66 x x x x x x x
21 45.68 48.12 2.44 q22.3 LOH 63 x x x x x x x
8 112.88 146.36 33.47 q23.3–q24.3 OCL 235 x x x x x
9 0 44.41 44.41 p24.3–p11.2 LOH 283 x x x x x
20 0 11.90 11.90 p13–p12.2 LOH 136 x x x x x
1 26.08 107.60 81.51 p36.11–p13.3 LOH 717 x x x x
20 31.89 32.83 0.93 q11.21–11.22 LOH 15 x x x x
22 16.39 42.11 25.72 q11.1–q13.2 LOH 433 x x x x
22 42.45 42.77 0.31 q13.2 LOH 9 x x x x
19 0.03 20.88 20.85 p13.3–p12 LOH 648 x x x
20 11.93 21.5 9.56 p12.2–p11.22 LOH 55 x x x
10 65.05 135.53 70.47 q21.3–q26.3 LOH 608 x x
(Continued )
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Chr Start 
(Mb)
End 
(Mb)
Length 
(Mb)
Cytobands Type # 
genes
DCIS 
1
DCIS 2 
complete
DCIS 2 
subclone
Primary 
tumor 
complete
Primary 
tumor 
subclone
Metastasis 
complete
Metastasis 
subclone
3 0 76.53 76.53 p26.3–p12.3 LOH 592 x
4 50.40 191.15 140.75 q11–q35.2 LOH 664 x
5 0 77.46 77.46 p15.33–q14.1 LOH 395 x
7 0 159.13 159.13 p22.3–q36.3 HL 1190 x
8 52.54 53.33 0.78 q11.22–11.23 LOH 3 x
8 55.37 67.35 11.98 q11.23–q13.1 LOH 59 x
8 68.34 86.56 18.22 q13.2–q21.2 LOH 76 x
9 130.73 141.21 10.48 q34.11–q34.3 LOH 252 x
10 0 65.05 65.05 p15.3–q21.3 LOH 387 x
14 18.80 42.09 23.28 q11.2–q21.1 LOH 227 x
15 19.96 42.13 22.16 q11.1–q15.1 HL 323 x
15 42.16 102.53 60.36 q15.1–q26.3 LOH 590 x
21 9.74 45.93 36.19 p11.2–q22.3 LOH 270 x
X 0 42.79 42.79 p22.33–p11.3 LOH 209 x
X 55.11 60.60 5.48 p11.21–q11.1 LOH 20 x
X 61.69 102.34 40.65 q11.1–q22.1 LOH 198 x
X 106.50 132.09 25.58 q22.3–q26.2 LOH 230 x
Copy number gain events
8 87.65 146.36 58.71 q21.3–q24.3 HCG 359 x x x x x x x
11 68.28 71.11 2.82 q13.2–q13.4 EHCG 26 x x x x x x x
11 75.90 85.33 9.43 q13.5–q14.1 VHCG 44 x x x x x x x
11 88.30 89.46 1.16 q14.3 CG 5 x x x x x x x
11 89.53 94.56 5.02 q14.3–q21 VHCG 46 x x x x x x x
16 1.40 2.79 1.39 p13.3 CG 80 x x x x x x x
16 15.50 18.43 2.93 p13.11–p12.3 CG 29 x x x x x x x
16 18.81 20.38 1.57 p12.3 CG 18 x x x x x x x
16 20.80 24.56 3.76 p12.3–p12.1 VHCG 50 x x x x x x x
16 27.67 31.99 4.32 p12.1–p11.2 VHCG 154 x x x x x x x
18 55.39 63.42 8.03 q21.31–q22.1 VHCG 42 x x x x x x x
17 41.44 43.34 1.89 q21.31 CG 58 x* x* x x x x
17 44.23 81.19 36.96 q21.31–q25.3 CG 542 x* x* x x x x
19 53.65 56.85 3.20 q13.42–q13.43 CG 181 x* x* x x x x
X 142.23 144.43 2.10 q27.3–q28 CG 5 x* x* x x x x
X 146.55 151.56 5.00 q27.3–q28 CG 45 x* x* x x x x
1 187.21 192.62 5.41 q31.1–q31.2 HCG 6 x* x* x x
1 192.62 197.10 4.47 q31.2–q31.3 CG 18 x* x* x x
1 197.10 215.74 18.64 q31.3–q41 HCG 202 x* x* x x
1 215.74 218.50 2.75 q41 CG 7 x* x* x x
20 21.37 26.06 4.98 p11.22–p11.1 CG 47 x* x* x x
(Continued )
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amounting to a total of 52 loss events and 43 gain events, 
as shown in Table 1. Copy number events exclusively 
found in the metastasis might contain oncogenic 
driver genes of the metastatic process, e.g. the extreme 
amplification of chromosome 8q22.2–23.2, a small region 
containing 53 genes. Copy number discordant genes 
between the primary tumor and the metastasis are listet in 
Supplementary Tables 5 and 6.
Two major homogenous subclones coexist in the 
asynchronous metastasis, seen in the ngCHG data as 
two distinct levels of loss in the Log2 ratio panel and the 
fraction of cells involved in the loss event is supported 
by the BAFs, as seen in Figure 5. A Level 1 loss is 
subclonal, thus involves only a fraction of the malignant 
cells, while a Level 2 loss is complete as it originates 
from all of the malignant cells. One subclone retains all 
Chr Start 
(Mb)
End 
(Mb)
Length 
(Mb)
Cytobands Type # 
genes
DCIS 
1
DCIS 2 
complete
DCIS 2 
subclone
Primary 
tumor 
complete
Primary 
tumor 
subclone
Metastasis 
complete
Metastasis 
subclone
20 33.71 52.66 18.95 q11.22–q13.2 CG 222 x* x* x x
22 46.66 50.65 3.98 q13.31–q13.33 HCG 29 x* x* x x
X 144.43 146.55 2.12 q27.3 CG 30 x* x* x x
X 151.56 155.05 3.49 q28 CG 133 x* x* x x
1 218.50 219.37 0.86 q41 HCG 5 x* x*
6 150.76 152.61 1.84 q25.1–q25.2 VHCG 9 x* x*
8 49.26 51.67 2.40 q11.21 VHCG 6 x* x*
8 51.67 52.54 0.86 q11.21–q11.22 CG 2 x* x*
8 53.34 55.37 2.03 q11.23 VHCG 10 x* x*
8 67.35 68.34 0.98 q13.1–q13.2 VHCG 17 x* x*
8 100.58 111.46 10.87 q22.2–q23.2 EHCG 53 x* x*
12 57.92 58.32 0.39 q13.3–q14.1 CG 22 x* x*
17 46.04 46.57 0.52 q21.32 VHCG 8 x* x*
17 47.36 81.08 33.71 q21.32–q25.3 VHCG 469 x* x*
19 53.65 56.85 3.20 q13.42–q13.43 VHCG 181 x* x*
20 29.89 31.89 1.99 q11.21 CG 47 x* x*
22 46.66 50.65 3.98 q13.31–q13.33 VHCG 29 x* x*
X 43.26 45.24 1.97 p11.3 CG 8 x* x*
X 45.59 51.07 5.48 p11.3–p11.22 CG 157 x* x*
X 51.64 54.31 2.67 p11.22 CG 67 x* x*
X 142.32 144.43 2.11 q27.3 HCG 5 x* x*
X 146.55 151.56 5.00 q27.3–q28 VHCG 45 x* x*
Figure 2: Copy number evolution of the studied cancer genome. All aberrations from the previous steps in tumor progression 
are retained in the later stages.
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Figure 3: Validated point mutations specified with B Allele Frequencies combined with copy number events within 
each step of malignant progression. NS: Nonsynonymous SNV. FS: Frameshift. S: Splicing. SG: Stopgain SNV.
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of the copy number aberrations from previous steps as 
well as an additional Level 2 loss on chromosome 10q, 
which likely constitutes an early event in the metastasis 
clone, as it is present in all of the metastatic cells. Another 
subclone contains all the aforementioned aberrations and 
17 additional Level 1 losses. The existence of two distinct 
metastatic subclones are supported by the BAFs, as 
complete and subclonal losses are accompanied by BAFs 
splitting out completely towards 0 and 1 and intermediate 
BAFs, respectively. Chromosome 7 and chromosome 
15q11.1–15.1 deviates from this rule as they display 
Level 2 losses accompanied by BAFs around 0.5. This 
phenomenon may be explained by a homozygote loss in 
one of the subclones of the metastasis, while the other 
subclone has retained the two alleles. The BAFs of 0.5 
represents the allele distribution of the subclone retaining 
the two alleles. The homozygote loss of chromosome 7 
and chromosome 15q11.1–15.1 reaches almost the same 
Log2 ratio loss level (Level 2) as the heterozygote loss 
levels of the entire distant metastasis, implying that the 
two subclones are approximately the same population size.
Point mutations reveal potential drivers affected 
by both LOH and nonsynonymous mutation
Three of the exact point mutations, in the TP53, 
NPAS2 and MYLK gene, are annotated to be previously 
found in cancer studies according to the Catalogue Of 
Somatic Mutations In Cancer (COSMIC) database 
(http://www.sanger.ac.uk). Only TP53, with its well-
known role in numerous cancers and PER1, which is 
found to be involved in translocations in leukaemias, are 
included in the cancer gene census list [13] (http://cancer.
sanger.ac.uk/cancergenome/projects/census). A thorough 
litera ture search was performed on the 65 genes affected 
by point mutations. Six genes including TP53, LOXL3, 
ARID1B, PAPPA, CYP3A43 and FAT4 were obviously 
relevant in the context of cancer. Not surprisingly, the 
tumor suppressor gene TP53 (17p13.1) is affected 
by both LOH and a point mutation, that is predicted 
damaging by SIFT, Polyphen2 and MutationTaster, in all 
stages of progression. Most noticeable are the frameshift 
deletion in LOXL3 which is also hit by both LOH in all 
Figure 4: Venn diagram showing the mutational concordance of validated somatic mutations between the steps in 
malignant progression based on targeted deep sequencing.
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samples, and the nonsynonymous mutations in ARID1B 
(6q25.3) and PAPPA (9q33.1), which are affected by 
LOH in all tumor stages but exclusively hit by point 
mutations in the asynchronous metastasis, suggesting that 
these genes might be involved in metastatic progression. 
The mutations are predicted to be deleterious by all three 
functional prediction scores and reduced expression 
of the LOXL3 gene and PAPPA gene are found to 
be significantly associated with shorter recurrence 
free survival (RFS) with p-value 3.4e-7 and p-value 
1.5e-7, respectively, according to the gene expression 
data provided by KM Plotter [14] (Kaplan Meier plots for 
the two genes are shown in Supplementary Figures 5–6). 
The CYP3A43 gene (7q22.1) is affected by a point 
mutation in all tumor steps and in addition LOH in the 
asynchronous metastasis. The nonsynonymous mutation 
is predicted to be highly deleterious and gene expression 
data show a highly significant relationship between 
low expression of the gene and reduced RFS ( p-value 
1.5e-9) (Kaplan Meier plot is shown in Supplementary 
Figure 7). The FAT4 gene is affected by both LOH 
and a nonsynonymous mutation predicted deleterious 
exclusively in the metastasis and low expression 
of the gene is significantly associated with reduced 
RFS ( p-value 4.7e-5) (Kaplan Meier plot is shown in 
Supplementary Figure 8).
Subclonal copy number events and deep 
sequencing frequencies of point mutations reveal 
clonal evolution and suggest the occurrence of 
catastrophic events
Density plots of mutation frequencies of validated 
somatic nonsynonymous point mutations, not affected by 
copy number events, are displayed in Supplementary Figures 
9–12. Homogeneity of mutation frequencies within DCIS 1 
is seen, supporting that DCIS 1 is monoclonal. Density plots 
of DCIS 2 and primary tumor illustrate subclonality with 
two major peaks, again supporting copy number data. The 
subclonality within the asynchronous metastasis is mostly 
characterized by the subclonal copy number loss events, 
but also supported by a few point mutations not affected by 
concurrent copy number aberrations.
Figure 6 displays the clonal evolution of the studied 
cancer genome in a plot of genetic events in molecular 
time. A driver event provides a selective advantage for a 
cell creating a subclone with new, additional mutations, 
while retaining the old as imprints in the genome, which 
is in accordance with a model of linear progression. The 
purification of subclonally occuring somatic aberrations 
in the primary tumor to complete events of the metastasis 
provides evidence of a single cell to be ancestor of the 
metastatic lesion.
Figure 5: Genome-wide display of copy number events of the asynchronous metastasis. The top panel displays Log2 ratios 
and the panel below displays BAFs of known SNPs heterozygote in the germline. Two prominent subclones within the asynchronous 
metastasis are revealed by two distinct levels of loss in the Log2 ratio plot, supported by the BAFs, displaying the fraction of cells 
participating in the event. Level 1 losses, originating from only a subclone of malignant cells, are accompanied by BAFs splitting out at an 
intermediate level. Level 2 losses, shared by all the malignant cells of the metastasis, are accompanied by BAFs splitting out to the level 
corresponding to a complete heterozygote loss.
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DISCUSSION
We set out to illuminate three aspects of breast 
cancer progression, the first being the controversy between 
the two fundamental models of metastatic progression. 
According to the parallel progression model, the metastasis 
founder cell disseminates early from the primary tumor, 
resulting in independent accumulation of genetic events in 
the metastasis. Concordantly, due to the inherent genomic 
instability of malignant cells one must also expect further 
genomic development in the primary tumor from the time 
point of dissemination of the metastatic cell to the time 
point of mastectomy. Hence, in order to provide evidence 
for the parallel progression model, one would expect 
to see genetic events exclusive to the primary tumor. 
However, this is not the case in our study. At its simplest, 
the model of linear progression does not take further 
genetic evolution of the disseminated cells into account. 
We find considerable additional genetic evolution in the 
metastatic lesion. We report a model of linear progression 
with relatively late dissemination from the primary tumor 
and additive accumulation of somatic events, also in the 
late stage of progression leading to genomic discordance 
between primary tumor and metastasis.
Next, our data are also informative for the 
phenomenon of clonal diversity within a cancer cell 
population. A stepwise accumulation of aberrations 
in several equally competitive lineages would result 
in a clonally diverse tumor with branching evolution 
of multiple independent and prominent subclones. A 
completely monoclonal tumor results if one lineage 
completely outgrows the others and no additional genetic 
aberrations conferring a selective advantage in the 
population are acquired. An intermediate scenario arises if 
the bulk of the tumor contains a certain set of aberrations 
and a subclone with additional aberrations, mediating a 
selective advantage to the progeny, arises relatively late 
in molecular time allowing the two subpopulations to 
coexist. Our study reveals the latter model of cancer cell 
evolution.
The third aspect is the degree of homogeneity within 
a cancer cell subclone, which addresses the question of 
stepwise versus catastrophic acquisition of novel events. 
A stepwise acquisition of somatic events within a lineage 
would most likely entail a number of consecutive subclones 
with varying fractions of malignant cells harboring the 
different aberrations, provided that none of the novel 
aberrations confer a significant selective advantage 
allowing it to outperform all other consecutive subclones. 
If a catastrophic event mediated the selective sweep 
by creating many aberrations at the same time or in a 
series of highly compressed events in molecular time, all 
the cells within the subclone will carry the aberrations. 
Thus, a density plot with mutational frequencies 
comprised of two peaks can suggest the appearance of a 
catastrophic event. The existence of two distinct levels of 
Figure 6: The evolution of clonal populations within the different steps of malignant progression of the studied cancer 
genome. The three vertical lines to the left represent analysis of the three topologically separated tissue samples and the vertical line to the 
right represent analysis of the metastasis, which is separated from the other malignant steps by both space and time. The increase in color 
intensity reflects the acquisition of additional somatic events.
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copy number loss, supported by the allelic fractions in the 
BAFs, are found in the metastasis revealing that an array 
of loss events private to the metastasis originates from the 
same fraction of cells. Hence, copy number data suggests 
evidence of a catastrophic event resulting in 17 additional 
loss events in a subpopulation of metastatic cells. Whether 
a catastrophic driver event comprise a single catastrophic 
event like chromothripsis or result from several, highly 
compressed events in molecular time, providing significant 
selective advantage to the progeny and thus resulting in 
a homogenous subclone, cannot be concluded from this 
study.
Naturally, the resolution of the ngCGH assay does 
not allow identification of very small subclones. Due to 
the inherent instability of cancer genomes, molecular 
heterogeneity constantly arises in a cancer cell population; 
the key factor is whether the new aberrations confer a 
selective advantage to the progeny. The frequency of a few 
point mutations drops during progression, suggesting that 
they are present in the less competitively advantageous 
clone and some mutations most likely are lost in the 
metastasis due to copy number loss events.
Molecular heterogeneity already within DCIS 
supports the idea of clonal selection toward invasive 
disease, where some malignant cells, in accordance with 
Darwinian evolution, in addition to the founder genetic 
aberrations, acquire aberrations enabling them to fulfill the 
requirements of invasion. This also applies for the later 
stages of malignant progression. Biological phenomena 
such as invasiveness, drug resistance and the ability to 
metastasize constitute evolutionary bottlenecks for the 
malignant cells, forcing them to acquire new abilities. 
Our study reveals evolution of copy number events 
and point mutations during breast cancer progression, a 
phenomenon influenced by several factors including time, 
increased genomic instability and selection pressures 
provided by treatment and endogenous immunological 
and microenvironmental factors. Clonal heterogeneity 
has been linked to poor clinical outcome in chronic 
lymphocytic leukemia [15] and in breast cancer [16]. In 
our patient only one subclone was found, which gave rise 
to the metastasis.
This proof of principle study, limited to only one 
patient, calls for extensions on a larger patient material. 
Breast cancer is known to display both inter-tumoral and 
intra-tumoral heterogeneity [17] and thus, the findings of 
this study are not comprehensively covering evolution of 
any breast cancer genome.
The studied patient had undergone neo-adjuvant 
chemotherapy, thus, all tumor samples of this study have 
survived the selection pressures provided by treatment. A 
tissue specimen prior to the neo-adjuvant chemotherapy 
and endocrine therapy might have contained non-resistant 
tumor clones and the cancer genome of our study likely 
represents a highly malignant and therapy-resistant cancer 
as the disease progresses in spite of extensive treatment. 
Furthermore, one could imagine different genome 
evolution if additional distant metastases were analyzed 
from the patient. Significant discordance in estrogen 
receptor and progesterone receptor status have been 
reported between different distant breast cancer metastases 
within the same patient [18].
Patient tailored medicine stresses the therapeutic 
relevance of uncovering the genomic concordance 
between a primary breast cancer and its metastases as 
primary tumors in clinical practice are used as surrogates 
for systemic disease. This highlights the need for studies 
elucidating genetic changes during progression of the 
disease. Relatively few studies have reported genomic 
copy number evolution during breast cancer progression 
using comparative genomic hybridization (CGH) [19, 20], 
arrayCGH [21, 22], multiplex ligation probe amplification 
(MLPA) [23] and targeted next generation sequencing 
[24]. Concordant with our results, previous global studies 
have found relatively similar genetic composition of 
primary breast cancers and matched metastases, however 
with some genetic divergence [25, 26].
The genomes of cancer cells acquire extensive 
genomic alterations due to increasing genomic instability 
but a significant proportion of these events are merely 
passenger events that do not provide any selective 
advantage for the cell. Distinguishing driver mutations 
and genes from passengers at different steps of malignant 
progression is the major challenge of cancer genomics, 
complicated by the fact that the roles of driver and 
passenger genes may change during progression of the 
disease [17]. In our study, the most obvious driver gene 
candidates based on literature search include TP53, 
LOXL3, ARID1B, PAPPA, FAT4 and CYP3A43. However, 
all the altered genes of the studied cancer genome 
are potential drivers. Genes altered exclusively in the 
metastasis are potentially new metastasis suppressor 
genes (MSGs) or genes that orchestrate the expression 
of several MSGs as recently suggested [27]. However, it 
must be stressed that copy number gains or losses does not 
automatically result in altered expression of the affected 
genes as it is likely that many genes are compensatory 
repressed or induced either by regulation of transcription 
factors or epigenetic regulation. Epigenetic changes play 
key roles in cancer [28] and recently a metastasis-specific 
methylation signature was reported [29], however, this 
layer in cancer biology was not included in our study.
In summary, we provide evidence for linear 
progression of metastatic disease in which dissemination 
from the primary tumor occurs relatively late in molecular 
time. Our study reveals common ancestry of the malignant 
cells and that early acquired copy number aberrations as 
well as point mutations are retained as imprints in the 
cancer genome, but also shows substantial acquisition 
of additional aberrations in the metastasis. We report 
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limited tumor heterogeneity from ongoing clonal linear 
evolution with continuous positive selection at every 
stage of malignant progression, where previously acquired 
aberrations coexist with newly acquired aberrations. The 
emergence of new aberrations in the metastasis reveal 
incomplete concordance between early tumor stages 
and systemic disease and emphasizes the importance of 
genomic analysis on not only of the primary tumor but 
also on metastatic tissue at recurrence in order to offer the 
patients molecularly targeted therapy.
METHODS
Patient material
Exome sequencing was performed on successive 
tumor samples from a 58 year-old breast cancer patient 
with estrogen receptor positive, HER2-negative, node 
positive invasive ductal carcinoma, initially treated with five 
series of neo-adjuvant Cyclophosphamide, Epirubicin and 
Fluorouracil (CEF). Ductal Carcinoma in Situ (DCIS) from 
two topologically different regions adjacent to the primary 
tumor and the primary tumor measuring 50 mm were secured 
during primary surgery and stored at –80°C until sample 
preparation. Following mastectomy, the patient received 
four series of Taxotere/Gemcitabine and radiation therapy. 
In parallel, the patient was initially treated with Tamoxifen 
and after 2.5 years the endocrine treatment was changed to 
Anastrozole. In spite of the extensive therapy and ongoing 
endocrine treatment, the patient experienced recurrence after 
4.05 years and later succumbed to the malignant disease. An 
asynchronous metastasis was biopsied from a contralateral 
periclavicular lymph node metastasis. Haematoxylin-eosin 
sections of all tissue samples were reviewed by a certified 
pathologist ensuring the diagnosis and a content of malignant 
cells of 75% at minimum. A start amount of 20–30 mg fresh 
frozen tissue (asynchronous metastasis 5 mg) was used for the 
purification process. Tissue disruption and homogenization 
was performed using TissueLyser (Qiagen) and purification 
of DNA was performed using AllPrep DNA/RNA Mini Kit 
(Qiagen). The primary tumor and matched normal tissue were 
stored as formalin-fixed paraffin-embedded (FFPE) tissue. 
The FFPE blocks were cut in 30–40 sections of 10 μm and 
DNA extracted using AS1000 Maxwell 16 (Promega, USA).
The patient consented to participate in the study and 
for the data to be published. The study was approved by 
the Ethical Committee of Region Syddanmark and notified 
to the Danish Data Protection Agency.
Library construction and exome sequencing
Exome enrichment was performed with Illumina’s 
TruSeq DNA Sample Preparation and sequenced on the 
Illumina HiSeq 1500 platform. FASTQ files were aligned 
to the human reference genome GRCh37 (feb.2009) 
using the Novoalign v. 3 algorithm (http://www.novocraft.
com) at default parameters. Removal of duplicate reads, 
recalibration and local realignment around indels was 
performed using Best Practices pipeline v. 2.7 [30]. The 
result was mean coverage rates in the exome region 
between 89 x and 148 x (Supplementary Table 1).
Copy number profiling and correction for 
aneuploidy
The Nexus 7.5 software (BioDiscovery) was applied 
for the detection of somatic copy number events using the 
ngCGH software (http://github.com/seandavi/ngCGH), 
in which the processing of tumor and process-matched 
normal sequencing BAM files computes a pseudo-CGH 
using simple coverage counting on the tumor reads relative 
to normal reads. Each window is defined by 1000 reads in 
the normal tissue BAM file. Within each defined genomic 
window the number of reads in the tumor is quantified 
and a ratio is made between the number reads in the tumor 
and the number of reads in the normal. Finally, a Log2 
transformation is applied to each ratio and the entire vector 
of the results is then centered by subtracting the median. 
A diploid region (ratio 1:1) results in a Log2 ratio of 0 
and the probes are placed at baseline. A single copy gain 
in the tumor sample (ratio 3:2) results in a Log2 ratio of 
0.58, while a heterozygote loss in the tumor sample (ratio 
1:2) results in a Log2 ratio of –1. Naturally, admixture of 
normal cells in the sequenced cancer sample compresses 
the Log2 ratio towards the baseline. The ngCGH software 
applies Fast Adaptive States Segmentation Technique 
(FASST2) segmentation to make calls. The minimum 
number of probes per call was set to 10. All other 
parameters were run by default. Cancer sample aneuploidy 
may introduce bias in establishing the Log2 Ratio baseline 
for copy number calling. True diploid regions in the cancer 
sample were detected, displaying BAF around 0.5, and the 
Log2 ratio baseline were adjusted according to these.
The primary tumor DNA in this study originates 
from FFPE tissue, a storage form known for posing 
technical challenges. We found the noise introduced by 
the formalin fixation in the ngCGH assay to be reduced by 
matching the FFPE tissue derived sequencing data with 
normal sequencing data also originating from FFPE tissue.
To supplement the computed ngCGH Log2 ratios, 
which constitute genomic quantity measurements, 
combined files were created, adding B Allele Frequencies 
(BAFs) for the tumor sample to be displayed in a panel 
below. The BAFs reveal the allele distribution between 
the reference allele (A allele) and the alternative allele 
(B allele) of the tumor sample and is calculated as 
BAF = B  allele  frequency
A + B  allele  frequency
.
The BAFs for the ngCHG plots included only 
germline heterozygote positions with known SNPs, 
annotated by dbSNP (version 135), and covered by at least 
Oncotarget5647www.impactjournals.com/oncotarget
30 × in both tumor and normal sample. Therefore, in the 
case of no copy number event in the tumor sample, the 
BAF in this region is 0.5. If all the sequenced cells of a 
region have lost one of the two alleles, the BAFs would 
split out to 0 and 1. The deviation from a 0/1 split out of 
BAFs in a complete heterozygote loss event reflects the 
degree of normal cell admixture in the tumor sample. A 
subclonal event results in intermediate BAFs as only a 
fraction of cells have lost one of the alleles.
Point mutation and indel calling
The BAFs reported from the somatic point mutation 
and indel calling are also calculated as 
BAF = B  allele  frequency
A + B  allele  frequency
.
and in this context the BAF depicts the percentage of 
somatic mutation alternative reads in the tumor sample. 
Variant calling was performed using Varscan 2 [31] 
version 2.3.6. Included were positions with normal tissue 
read depth of min. 10 and normal tissue homozygote for 
the reference allele defined by BAF < 0.02. Only positions 
with min. 3 alternative reads and BAF > 0.15 in one of 
the tumor samples were included and mutation noted 
when BAF > 0.05. The variants were annotated with 
Annovar [32]. Known SNPs with an allele frequency 
> 1% were excluded. Validation with deep sequencing 
using SureSelect (Agilent) target enrichment resulted in 
a mean coverage of 377 ×. The functional significance 
of the validated nonsynonymous SNVs were assessed by 
the functional prediction algorithms SIFT [33], PolyPhen2 
[34] and Mutation Taster [35]. Gene expression levels 
from breast cancer studies with outcome data were utilized 
using the Kaplan Meier plotter online tool (http://www.
kmplot.com) [14] in order to evaluate the effect of altered 
gene transcription levels on recurrence free survival.
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